Document Detail

Variable response to long-term corticosteroid therapy in chronic beryllium disease.
MedLine Citation:
PMID:  15596705     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Chronic beryllium disease (CBD) shares many of its characteristics with sarcoidosis and is often treated with corticosteroids. There is limited available literature regarding the effect of long-term corticosteroid therapy on the natural history of CBD. METHODS AND MATERIALS: We conducted an observational retrospective study of six patients with CBD who received prolonged corticosteroid treatment with a mean pulmonary function test follow-up period of 10.1 years. Five of the six patients were exposed to beryllium at the same workplace. The diagnosis in four of the six cases was confirmed by a positive beryllium lymphocyte proliferation test result on blood or BAL fluid. Periodic pulmonary function tests were analyzed in relation to removal from beryllium exposure and treatment with corticosteroids. MEASUREMENTS AND RESULTS: Two broad patterns of response were noted in these patients. The first pattern seen in two patients showed no improvement in FVC or diffusion capacity of the lung for carbon monoxide (Dlco) with corticosteroids. However, a significant improvement in these parameters was noted on cessation of beryllium exposure in one of the two patients. The second pattern showed an initial improvement in FVC and Dlco with corticosteroids, which was not sustained. An improvement was noted on stopping beryllium exposure. CONCLUSIONS: The response to long-term corticosteroids in CBD, quite like that in sarcoidosis, is variable. Significant lung function improvement may be seen following cessation of beryllium exposure.
Akshay Sood; William S Beckett; Mark R Cullen
Related Documents :
328415 - The effect of alternate-day prednisone therapy on cortisol secretion rate in corticoste...
9778225 - Intravenous pulse administration of cyclophosphamide versus daily oral treatment in pat...
19769705 - A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional...
10983735 - Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary di...
25340055 - Aqp4 autoantibody assay performance in clinical laboratory service.
24104775 - Long-term patient satisfaction with michigan four-wall sacrospinous ligament suspension...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chest     Volume:  126     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-14     Completed Date:  2005-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2000-7     Citation Subset:  AIM; IM    
Division of Pulmonary and Critical Care Medicine, Southern Illinois University School of Medicine, 701 North First Street, Room D434, PO Box 19636, Springfield, IL 62794-9636, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Berylliosis / drug therapy*,  pathology,  physiopathology
Chronic Disease
Glucocorticoids / therapeutic use*
Lung / pathology
Pulmonary Diffusing Capacity
Vital Capacity
Reg. No./Substance:
Comment In:
Chest. 2004 Dec;126(6):1730-2   [PMID:  15596666 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemot...
Next Document:  Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity.